Valsartan therapy in the treatment of thalassemia-induced dyspnea
Not Applicable
- Conditions
- secondary Pulmonary hypertension due to the Thalassemia.Other secondary pulmonary hypertension
- Registration Number
- IRCT2012100611022N1
- Lead Sponsor
- School of medicine- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
thalassemia intermedia or major, age = 10 years, systolic pulmonary artery pressure = mmhg25.
Exclusion criteria: Allergy to sildenafil or valsartan, incidence the side effects of drugs, no consent to continue the study, using other drugs which are in interaction with study drugs, increased NYHA function class of dyspnea
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pulmonary arterial pressure. Timepoint: begining of the study, the last day of first month and the last day of 6th month. Method of measurement: Echocardiography.
- Secondary Outcome Measures
Name Time Method Dyspnea. Timepoint: begining of the study, the last day of first month and the last day of 6th month. Method of measurement: NYHA function class.